Navigation Links
A gene family that suppresses prostate cancer
Date:3/13/2014

ITHACA, N.Y. Cornell University researchers report they have discovered direct genetic evidence that a family of genes, called MicroRNA-34 (miR-34), are bona fide tumor suppressors.

The study is published in the journal Cell Reports, March 13.

Previous research at Cornell and elsewhere has shown that another gene, called p53, acts to positively regulate miR-34. Mutations of p53 have been implicated in half of all cancers. Interestingly, miR-34 is also frequently silenced by mechanisms other than p53 in many cancers, including those with p53 mutations.

The researchers showed in mice how interplay between genes p53 and miR-34 jointly inhibits another cancer-causing gene called MET. In absence of p53 and miR-34, MET overexpresses a receptor protein and promotes unregulated cell growth and metastasis.

This is the first time this mechanism has been proven in a mouse model, said Alexander Nikitin, a professor of pathology in Cornell's Department of Biomedical Sciences and the paper's senior author. Chieh-Yang Cheng, a graduate student in Nikitin's lab, is the paper's first author.

In a 2011 Proceedings of the National Academy of Sciences paper, Nikitin and colleagues showed that p53 and miR-34 jointly regulate MET in cell culture but it remained unknown if the same mechanism works in a mouse model of cancer (a special strain of mice used to study human disease).

The findings suggest that drug therapies that target and suppress MET could be especially successful in cancers where both p53 and miR-34 are deficient.

The researchers used mice bred to develop prostate cancer, then inactivated the p53 gene by itself, or miR-34 by itself, or both together, but only in epithelium tissue of the prostate, as global silencing of these genes may have produced misleading results.

When miR-34 genes alone were silenced in the mice, the mice developed cancer free. When p53 was silenced by itself, there were signs of precancerous lesions early in development, but no cancer by 15 months of age. When miR-34 and p53 genes were both silenced together, the researchers observed full prostate cancer in the mice.

The findings revealed that "miR-34 can be a tumor-suppressor gene, but it has to work together with p53," Nikitin said.

In mice that had both miR-34 and p53 silenced concurrently, cancerous lesions formed in a proximal part of the prostrate ducts, in a compartment known to contain prostate stem cells. The early lesions that developed when p53 was silenced alone occurred in a distal part of the ducts, away from the compartment where the stem cell pool is located. This suggested there was another mechanism involved when p53 and miR-34 were jointly silenced.

Also, the number of stem cells in mice with both p53 and miR-34 silenced increased substantially compared with control mice or mice with only miR-34 or p53 independently silenced.

"These results indicated that together miR-34 and p53 regulate the prostate stem cell compartments," said Nikitin.

This is significant, as cancer frequently develops when stem cells become unregulated and grow uncontrollably, he said.

Researchers further found that p53 and miR-34 affect stem cell growth by regulating MET expression. In absence of p53 and miR-34, MET is overexpressed, which leads to uncontrolled growth of prostate stem cells and high levels of cancer in these mice.

Future work will further examine the role of p53/miR-34/MET genes in stem cell growth and cancer. The findings have implications for many types of cancer.


'/>"/>

Contact: Joe Schwartz
Joe.Schwartz@cornell.edu
607-254-6235
Cornell University
Source:Eurekalert

Related biology news :

1. Sequencing hundreds of nuclear genes in the sunflower family now possible
2. Price Family Foundation funds research collaboration between Albert Einstein College of Medicine and University of Oklahoma
3. Price Family Foundation gift will create groundbreaking structural biology institute
4. Study of rodent family tree puts brakes on commonly held understanding of evolution
5. Crown of Venezuelan paramos: A new species from the daisy family, Coespeletia palustris
6. Population Council to present more than 40 studies at International Conference on Family Planning
7. Family Resiliency Center helps study how food-bank clients afford basic non-food items
8. Family matters: Evolutionary relationships among species of magic mushrooms shed light on fungi
9. Family tree of fish yields surprises
10. PatientStream announces the industrys first Multilingual family waiting room board
11. Family studies suggest rare genetic mutations team up to cause schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/14/2016)... Nov. 14, 2016  Based on its ... Frost & Sullivan recognizes FST Biometrics with ... for Visionary Innovation Leadership. FST Biometrics emerged ... identification market by pioneering In Motion Identification ... instant, seamless, and non-invasive verification. This patented ...
(Date:6/22/2016)... June 22, 2016 On Monday, the Department ... industry to share solutions for the Biometric Exit Program. ... and Border Protection (CBP), explains that CBP intends to ... the United States , in order ... defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... December 01, 2016 , ... ... findings demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) ... Antonio Breast Cancer Symposium. Using molecular test results from tumors with previously ...
(Date:12/2/2016)... ... 01, 2016 , ... DrugDev believes the only way to achieve ... experience. All three tenets were on display at the 2nd Annual DrugDev User Summit ... sponsor, CRO and site organizations to discuss innovation and the future of clinical research. ...
(Date:12/2/2016)... , Dec. 1, 2016   SurePure, Inc. ... announced today that the Company has concluded an agreement ... right for a 90-day period to acquire units of ... of approximately USD 3.7 million.  Concurrently ... with Tamarack under which Tamarack will seek regulatory approvals ...
(Date:11/30/2016)...  GenomOncology today announced the appointment of Joshua F. ... Dr. Coleman will oversee clinical content development and ... The GenomOncology software suite empowers molecular pathologists with a seamless ... decision support, from quality control through reporting. ... , , ...
Breaking Biology Technology: